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Abstract Gastric cancer cells express a broad spectrum of
the growth factor/cytokine receptor systems that organize
the complex interaction between cancer cells and stromal
cells in tumor microenvironment, which confers cell growth,
apoptosis, morphogenesis, angiogenesis, progression and
metastasis. However, these abnormal growth factor/cytokine
networks differ in the two histological types of gastric
cancer. Importantly, activation of nuclear factor-kB pathway
by Helicobacter pylori infection may act as a key player for
induction of growth factor/cytokine networks in gastritis and
pathogenesis of gastric cancer. Better understanding of these
events will no doubt provide new approaches for biomarkers
of diagnosis and effective therapeutic targeting of gastric
cancer.
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Abbreviations
H. pylori helicobacter pylori
Cag A cytotoxin-associated gene A
NF-kB nuclear factor-kB
IL interleukin
TNF tumor necrosis factor
COX cyclooxygenase
VEGF vascular endothelial growth factor
MMP matrix metalloproteinase
iNOS inducible nitric oxide synthase
TGF transforming growth factor
EGF epidermal growth factor
FGF fibroblast growth factor
Introduction
Gastric cancer remains the world’s second commonest
malignancy [1]. However, there is substantial variation in
gastric cancer incidence with the highest rates reported
from Korea, Japan and Eastern Europe, whereas Western
Europe and the US have low incidence rates. The global
burden of gastric cancer is shifting rapidly from the
developed world to the developing world.
Recent evidence indicates that a large number of genetic
and epigenetic alterations in oncogenes, tumor suppressor
genes and genetic instability as well as telomerase
activation determine a multi-step process of gastric carci-
nogenesis [1, 2]. However, these molecular events found in
gastric cancer differ depending upon the two histological
types, intestinal and diffuse types of gastric carcinoma,
indicating that intestinal and diffuse type carcinomas have
distinct genetic pathway [2]. The evolution of intestinal
tumors is generally characterized as progressing through a
number of sequential steps including gastritis, intestinal
metaplasia, dysplasia and carcinoma, while no preceding
steps are detected in the pathogenesis of diffuse carcinoma
other than the obvious chronic gastritis.
The most significant advance in the pathogenesis of gastric
cancer is involved with the recognition of the roleof H. pylori
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H. pylori infection is associated with chronic inflammation
and multistage process of gastric carcinogenesis [3].
Both the complex host/microbial interaction and growth
factor/cytokine networks induced by H. pylori are mediated
by the microenvironment that is an indispensable player in
the multistage process of gastric carcinogenesis. This
review provides an overview of H. pylori-induced inflam-
mation and the molecular and cellular events of tumor
microenvironment that underlie gastric cancer.
H. Pylori-Induced Inflammation Implicated in Gastric
Carcinogenesis
There are several of H. pylori-virulence associated genes
such as cagA, vacA, iceA and babA[ 1]. Among them, the
cagA gene is localized at one end of the cag pathogenicity
island (PAI) [4]. The cagPAI encodes components of a type
IV secretion system, by which the cagA gene product,
CagA, is delivered into gastric epithelial cells [5]. The
cagA-positive H. pylori strains are associated with higher
grade of gastric inflammation and higher risk of gastric
cancer than the cagA negative strains [6]. Prinz et al. [7]
reported that CagA+/VacAs1+ strains of H. pylori that are
blood group antigen-binding adhesion (BabA2) positive are
associated with activity and chronicity of gastritis. Adherence
of H. pylori via BabA2 may play a key role for efficient
delivery of VacA and CagA. Moreover, Hatakeyama [8]
recently reported that CagA binds an Src homology 2 (SH2)
containing tyrosine phosphatase SHP-2 in a tyrosine phos-
phorylation-dependent manner and activates the phosphatase
activity of SHP-2. Deregulation of SHP2 by CagA is an
important mechanism by which cagAp o s i t i v eH.pylori
promotes gastric carcinogenesis. Moreover, Hatakeyama [8]
found that East-Asian CagA shows stronger SHP2 binding
and greater biological activity than Western CagA. Differ-
ences in the biological activity of Western and East-Asian
CagA proteins, which are determined by variation in the
typrosine phosphorylation sites, may underlie the different
incidences of gastric cancer in these two geographic areas.
In addition to deregulation of SHP2 by CagA, H. pylori is a
potent activating factor of NF-kB in gastric epithelial cells [9].
Activation of NF-kB by H. pylori infection induces a variety
of gene expression including cytokines (IL-1, IL-6. IL-8, TNF
alpha), VEGF, COX2, iNOS, cell-cycle regular, MMP2,
MMP9 and adhesion molecules [10–12]. Successful eradica-
tion of H. pylori leads to down regulation of COX2 in the
epithelial and stromal cells [2]. High expression of COX2
mRNA, protein, and enzymatic activity is detected in the
tumor cells of gastric cancer [2]. Importantly, COX2 activity
is induced by a variety of mediators including inflammatory
cytokines such as TNF alpha, interferon-gamma and IL-1
[13]. COX2 facilitates tumor growth by inhibiting apoptosis,
maintaining cell proliferation and stimulating angiogenesis
within cancer cells [14].
H. pylori infection produces reactive oxygen and
nitrogen species that cause DNA damage, followed by
chronic gastritis and intestinal metaplasia [3]. Nitric oxide
generated by iNOS is converted to reactive nitrogen species
that bring about direct DNA mutation such as p53 and
protein damage, inhibition of apoptosis, and promotion of
angiogenesis [15]. Goto et al. [16] reported that the
expression of iNOS and nitro tyrosine in the gastric mucosa
was significantly high in H. pylori infected patients who
developed gastric cancer at least two years after the initial
biopsies.
Factors Associated with Increased Incidence of Gastric
Carcinoma
Three major factors, including environmental factors (diet,
obesity, cigarette smoking), host factors (H. pylori strains),
and genetic factors, cooperatively affect the genesis of
gastric cancer [2]. Of these factors, host genetic factors play
a critical role in susceptibility to gastric carcinogenesis.
El-Omar [17] reported that pro-inflammatory IL-1 gene
cluster polymorphisms increase the risk of gastric cancer
and its precursors in the presence of H. pyroli. Moreover,
the pro-inflammatory IL-1 genotypes are associated with an
increased risk of both intestinal and diffuse types of gastric
cancer [18]. In addition, TNF alpha and IL-10 genotypes
are viewed as independent risk factors for gastric cancer
[18]. The combination of three or four pro-inflammatory
cytokine polymorphisms affecting IL-1 beta (IL-1B-511T),
IL-1 receptor antagonist (IL-1RN*2), TNF alpha (TNF-
A-308A) and IL-10 (IL-10 haplotype ATA) results in a
highly significant increased risk of development of gastric
cancer [18]. However, we recently found that IL-10
haplotype (IL-10 GGCG) is associated with increased risk
of gastric cancer and high levels of plasma IL-10 serum in
atomic bomb survivors [19]. More recently, Ohyauchi et al.
[20] reported that IL-8 polymorphism is also associated
with increased risk of gastric cancer in the Japanese
population. These host genetic factors as well as H. pylori
strains may determine why some individual infected with
H.pylori develop gastric cancer while others do not.
Stem Cell Hyperplasia Induced by H. pylori
H. pylori infection induces stem cell hyperplasia in chronic
inflammation leading to increased mutation and DNA
methylation. Stem cells in the gastric epithelium have yet
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markers of normal human stem cells in the gastrointestinal
tact including Musashi1 (Msi-1), Hes-1 and nuclear beta-
catenin [21]. Msi-1 is an RNA binding protein that may be
necessary for stem cell maintenance and/or asymmetric cell
division. In human gastric epithelium, Msi-1 is expressed at
the proliferative regions of the antrum and fundic glands
but its expression is decreased in intestinal metaplasia
suggesting that Msi-1 is a marker of gastric progenitor cells
[22]. Interestingly, H. pylori infection strongly induces the
expression of Msi-1 that is correlated with H. pylori density
[23]. Ushijima group [24] recently reported that H. pylori
infection potently induces methylation of CpG islands
(LOX, HAND1, THBD and p41ARC), suggesting that H.
pylori induces DNA methylation in stem cells. Cell division
itself is a promoting factor for de novo DNA methylation.
The RNA component of telomerase, hTERC, and the
catalytic subunit, hTERT, are essential and the minimum
components that are required for telomerase activity [25].
Telomerase activity and TERT expression are necessary for
stem cell function [26]. In fact, we found that low levels of
telomerase activity exist in Ki-67-positive epithelial stem
cells, which simultaneously express hTERT protein and
hTERC protein in intestinal metaplasia of the stomach [27].
The levels of hTERT expression and telomerase activity are
in parallel with degree of H. pylori infection, suggesting that
telomerase competence of stem cell hyperplasia caused by H.
pylori infection may be linked to “chronic mitogenesis” that
can facilitate “increased mutagenesis”.
We previously reported that telomerase activity is present
in a majority of gastric cancer [2]. The approach for cancer
therapy targeting telomerase and/or telomeres has the
potential for innovative anti-cancer drugs. Telomestatin, a
G-quadruplex stabilizing agent found in natural products, is
highly selective for telomere G-quadruplex structures formed
by the 3’ overhang compared to other compounds [28].
Telomestatin preferentially induces apoptosis in cancer cells
or not in normal fibroblasts and epithelial cells [29].
Moreover, Kondo et al. recently reported that loss of
heterozygosity and histone hypoacetylation of the PINX1
gene, a possible telomerase inhibitor, are associated with
reduced expression in gastric carcinoma [30]. They also
revealed that telomerase activity is inhibited with trichostatin
(TSA) and nicotinamide (NAM) in gastric cancer cells even
if hTERT expression is not changed. These results provide a
possibility for cancer therapy with HAM [30].
Currently, a body of evidence indicates that bone
marrow-derived stem cells can engraft and differentiate
into nonhematopoietic cells of ectodermal, mesodermal and
endodermal tissues other than hematopoietic tissues. These
stem cells also contribute to cancer stroma in mouse models
[21]. Recently, Taketo group [31] found that SMAD4-
deficient mouse colorectal cancer cells produce CC chemo-
kine ligand 9 (CCL9) and recruit the MMP-expressing
immature myeloid cells (iMC) that express CC chemokine
receptor 1 (CCR1) and that lack of CCR1 prevents the
accumulation of MMP-expressing iMC at the invasion front
and suppresses tumor invasion. These exciting results
suggest that human gastric cancers also may have the
possibility to exhibit interaction between cancer cells and
bone marrow-derived stromal cells implicated in tumor
invasion, as majority of human gastric cancer is associated
with loss or dysfunction of TGF-beta signaling [2]. It
should be examined whether or not bone marrow-derived
cells in gastric cancer microenvironment produce MMP and
then encourage tumor cells to invade into the stroma.
Moreover, gastric cancer originating from bone marrow-
derived cells has been reported in mouse models [32].
However, Cogle et al. [33] reported that bone marrow stem
cells mimic cancer but do not initiate it in human cancers.
Molecular Mechanisms of Gastric Carcinogenesis
Multiple genetic and epigenetic alterations in oncogenes,
tumor suppressor genes, cell cycle regulators, cell adhesion
molecules and DNA repair genes, as well as genetic
instability and telomerase activation are responsible for
tumorigenesis and progression of gastric cancer [1, 2, 31].
Differences exist in the pathways leading to intestinal and
diffuse types of gastric carcinoma.
Inactivation of various genes including p16. hMHL1,
CDH1, RAR-beta2, pS2 and RUNX3 by DNA methylation
is involved in two distinct major genetic pathways of
gastric cancer [2, 3, 34]. Hypermethylation of the p16 and
of hMLH1 promoters is preferentially associated with
intestinal type gastric carcinoma, whereas concordant
hypermethylation of the CDH1 and RAR-beta2 promoters
is predominantly detected in diffuse type gastric carcinoma.
Loss or reduction of RUNX3 and pS2 expression by
promoter methylation is a common event in both types of
gastric carcinoma. In addition to promoter methylation,
acetylated histone H4 is reduced in the majority of both
types of gastric carcinoma [2]. Histone H4 is progressively
deacetylated from the early stage to the late stage of the
multi-step carcinogenesis of the stomach. Moreover, his-
tone H3 acetylation is associated with reduced p21 (WAF1/
CIP1) expression by gastric carcinoma [35].
Among these epigenetic events, RUNX3, a Runt domain
transcription factor involved in TGF-beta signaling, is
silenced in 63% gastric cancer as well as in 73% of
hepatocellular carcinoma, 70% of bile duct cancer, 75% of
pancreas cancer, 62% of laryngeal cancer, 46% of lung
cancer, 25% of breast cancer and 23% of prostate cancer
and 5% of colon cancer. Interestingly, inactivation of
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chronic gastritis, 28% of intestinal metaplasia, and 27% of
gastric adenoma, but not in chronic hepatitis B [2]. These
findings suggest that RUNX3 is a target for epigenetic gene
silencing already at early stage of gastric carcinogenesis.
In the multi-step process of intestinal type gastric
carcinoma, genetic instability and hyperplasia of hTERT
positive stem cells precede replication error at the D1S191
locus, DNA hypermethylation at the D17S5 locus, pS2
loss, RAR-beta2 loss, RUNX3 loss, abnormal transcripts of
CD44 and p53 mutation. All of these changes accumulate
in at least 30% of incomplete intestinal metaplasia and are
common events in intestinal type gastric cancer. An
adenoma to carcinoma sequence is observed on around
20% of gastric adenoma with APC mutations. Molecular
events associated with this sequence are loss of heterozy-
gosity and mutation of p53, reduced p27 expression, loss of
RUNX3, over-expression of cycline E and abnormal c-met
transcription. The resulting advanced intestinal type gastric
carcinomas frequently exhibit DCC loss, APC mutation, 1q
LOH, loss of p27, reduced TGF beta-receptor expression,
reduced nm23 and c-erbB2 gene amplification [1–3].
Meanwhile, diffuse type gastric carcinogenesis involves
LOH at chromosome 17p,LOH or mutation of p53, LUNX3
loss and mutation or loss of E-cadherin. Gene amplification
of K-sam, c-met and cycline E confers progression and
metastasis. Several of the above molecular events may be
present in mixed gastric cancer that have both intestinal and
diffuse components [1–3].
Meta-analysis of epidemiological studies and animal
models shows that both intestinal and diffuse types of
gastric cancer are equally associated with H. pylori
infection [36, 37]. However, H. pylori infection may play
a role only in the initial steps of gastric carcinogenesis.
Importantly, younger H. pylori-infected patients have a
higher relative risk for gastric cancer than older patients. In
general, diffuse type gastric cancers occur mostly in
younger patients. Hereditary diffuse gastric cancer caused by
germ line E-cadherin mutations is also observed in younger
age group [38]. We recently found that a low CagA IgG titer
is a useful biomarker to identify a high-risk of gastric cancer
and current smoking exhibits significantly higher risk for
diffuse type than intestinal type gastric cancers, while
radiation risk is significant only for nonsmokers and diffuse
type gastric cancers [39]. Differences in H. pylori strain,
patient age, exogenous and endogenous carcinogens and host
genetic factors may be implicated in two distinct major
genetic pathways for gastric carcinogenesis.
Abnormal Growth Factor/Cytokine Network in Gastric
Cancer
Gastric cancer cells express a wide array of growth factors
and cytokines that act via autocrine, paracrine and juxta-
crine mechanisms in the tumor microenvironment [2, 3].
These complex interactions between tumor cells and
stromal cells confer morphogenesis, angiogenesis, invasion
and metastasis [Fig. 1]. Again the expression of these
mediators varies depending on the histological subtype.
The EGF family including EGF, TGF alpha, cripto and
amphiregulin (AR) are commonly overexpressed in intestinal
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factor II (IGF II) and bFGF are predominantly overexpressed
in the diffuse type carcinoma. Co-expression of EGF/TGF
alpha and EGFreceptor correlates well with the biological
malignancy, as these factors induce metalloproteinase [3].
Overexpression of cripto is frequently associated with
intestinal metaplasia and gastric adenoma [3]. Akagi et al.
[40] reported that gastric cancer cells express neutrophilin-1
(NRP-1), a co-receptor for VEGF receptor 2 endothelial
cells. EGF induces both NRP-1 and VEGF expression,
suggesting that regulation of NRP-1 expression in gastric
cancer is intimately associated with the EGF/EGFR system.
IL-1 alpha is produced not only by activated macro-
phages but also by gastric cancer cells. It acts as an
autocrine growth factor for gastric carcinoma cells and
plays a pivotal role as a trigger for the induction of EGF
and EGF receptor [2, 3]. IL-6 also acts in an autocrine
fashion to stimulate gastric cancer cells. IL-1 alpha and IL-
6 both induces the expression of each other by tumor cells.
Serum IL-6 in patients with gastric cancer is significantly
correlated with tumor stage, depth of tumor invasion,
lymphatic invasion, venous invasion and hepatic metastasis,
suggesting that IL-6 may be useful for a prognostic factor
of gastric cancer [41]. Interestingly, Lin et al. [42] recently
found that IL-6 induces gastric cancer cell invasion via
activation of the c-Src/RhoA/ROCK signaling pathway.
Overexpression of these cytokines, IL-8 and growth factors
by the tumor cells may be caused mainly by constitutive
NF-kB activation due to constitutive activation of several
upstream kinases [12].
More than 80% of primary gastric cancer express IL-8 and
IL-8 receptor and this co-expression correlate directly with
tumor vasularity and tumor invasion [43]. IL-8 enhances
expression of EGF receptor, type IV collagenase (MMP9),
VEGF and IL-8 mRNA itself by gastric cancer cells, while
reducing E-cadherin mRNA expression [44]. Takehara et al.
[45] recently reported that the COX-2 pathway might be also
involved in IL-8 production in gastric cancer cells. In addition
toIL-8,majorityofgastric carcinoma expressIL-11andIL-11
receptor alpha and IL-11 promotes the migration of gastric
cancer cells by the activation of the phosphatidylinositol-3
kinase pathway [46]. Moreover, recent studies show that
expression of IL-12 and IL-18 also confers progression and
metastasis [47, 48].
The negative growth factor TGF beta is frequently
overexpressed in gastric carcinoma, particularly in diffuse
type carcinoma with productive fibrosis [2]. Hawinkels et
al. [49] reported that active TGF beta 1 is present in the
tumor cells and fibroblasts, and high tumor TGF beta1
activity are significantly associated with worse survival of
the patients. More importantly, recent in vivo and in vitro
studies of Mishra group [50, 51] demonstrate that inactiva-
tion of ELF/TGF-beta signaling plays a key role in the
development of gastric carcinoma. Embryonic Liver Fodrin
(ELF) is a beta-spectrin, an adaptor protein that plays an
essential role in the propagation of TGF beta signaling. She
found that loss of ELF and reduced Smad4 expression are
observed in human gastric cancer.
Angiogenic factors such as VEGF, bFGF and IL-8 are
produced by tumor cells and results neovacularisation
within gastric carcinoma [2]. VEGF promote mainly
angiogenesis and progression of intestinal type gastric
cancer while bFGF has a stronger association with diffuse
type gastric cancer. VEGF-C produced by tumor cells
participates in the development of lymph node metastasis.
Stromal cells, especially fibroblasts stimulated by growth
factors and cytokines such as IL-1 alpha, TGF alpha and
TGF beta secrete hepatocyte growth factor/scatter factor
(HGF/SF), which functions in a paracrine manner as a
morphogen or motogen [2, 3]. HGF/SF from stromal cells
binds to c-met on the tumor cells leading to enhanced
progression via activation of c-met pathways. Moreover,
keratinocyte growth factor (KGF) produced by gastric
fibroblasts binds to KGF receptor, K-sam on tumor cells,
resulting in the development of scirrhous type gastric
cancer [52].
Osteopontin(OPN),alsotermedEta-1(earlyT-lymphocyte
activation-1), which is a reported protein ligand of CD44, is
overexpressed in 73% of gastric cancer [2, 3]. The co-
expression of OPN and CD44 v9 in tumor cells correlates
with the nodal metastasis in diffuse type gastric cancer. Wu
et al. [53] recently reported that elevated plasma OPN level
is significantly associated with gastric cancer development,
invasive phenotype and survival, suggesting that plasma
OPN might have potential usefulness as a diagnostic and
prognostic factor for gastric cancer.
Regenerating islet-derived family, member 4 (Reg IV) is
expressed in gastric cancer, colon cancer and pancreas
cancer [54]. High Reg IV expression is associated with 5-
FU resistance in gastric and colon cancer cells by inhibiting
the mitochondrial apoptotic pathway, suggesting that
expression of Reg IV is a marker for prediction of
resistance to 5-FU chemotherapy in patients with gastric
cancer [55]. Reg IV also induces phosphorylation of EGF
receptor at Tyr992 and expression of Bcl2. Excitingly we
found that Reg IVas well as MMP-10 are able to be useful
for biomarkers to detect early stage of gastric cancer [56].
Moreover, Interferon inducible gene 6-16, GIP3 is also
expressed in gastric cancers and inhibits mitochondrial-
mediated apoptosis in gastric cancer cells, suggesting that
6-16 may be a new target for cancer therapy [57].
Wnt-5a is a representative of Wnt proteins that activate
the beta-catenin-independent pathway. However, the func-
tions of Wnt-5a in human cancer are controversial. Wnt-5a
inhibits proliferation, migration, and invasiveness in thyroid
tumor and colorectal cancer cell lines [58, 59], whereas
Growth factor/cytokine in gastric cancer 89Wnt-5a expression is correlated with cell motility and
invasiveness in melanoma cells and breast cancer cells with
tumor -associated macrophages [60, 61]. Kurayoshi et al.
[62] showed that expression of Wnt-5a is correlated with
aggressiveness of gastric cancer by stimulating cell migration
andinvasion.Wnt-5aactivatesPKCandJNK,therebyleading
totheactivationofFAKandpaxillin.Wnt-5aandextracellular
matrix bind to Frizzled (Wnt-5a receptor) and integrin, and
cooperatively activate a signaling cascade to stimulate cell
migration. Wnt-5a may be a novel biomarker of prognostic
factor and also a therapeutic target for gastric cancer [62].
These eventsof abnormal growth factor/cytokine networks
in the tumor microenvironment will no doubt provide a great
deal of information on new approaches for biomarkers and
effective therapeutic targeting of gastric cancer.
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